Back to News
Market Impact: 0.35
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo
Source: fool.com
Healthcare & BiotechCompany FundamentalsAnalyst Insights
AbbVie’s ABBV-466 nearly doubled Skyrizi’s Crohn’s remission rate in a Phase 2 study. Analysts view ABBV-466 as a potentially more effective follow-up to Skyrizi; the article provides no absolute remission rates or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
ABBV0.80
More News
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash